Compartmentalization of cAMP signaling in adipogenesis, lipogenesis, and lipolysis.
Rogne M., Taskén K.
Narrative Review, published in Horm Metab Res (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Horm Metab Res (2014)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25247872
- DOI
- 10.1055/s-0034-1389955
Abstract (original English)
Energy storage and release at times of food excess or fasting are carefully coordinated processes that depend on the appropriate differentiation of mesenchymal stem cells into mature adipocytes (adipogenesis) forming white adipose tissue (WAT) and on regulatory signals for storage (lipogenesis) or mobilization (lipolysis) of triacylglycerides (TAGs) from lipid droplets. It is widely recognized that cAMP signaling via protein kinase A (PKA) is important both in adipogenesis and for hormonal control and lipolysis in WAT. A kinase anchoring proteins (AKAPs) target PKA to distinct subcellular compartments in close proximity to its specific substrates thereby providing spatial and temporal specificity in the mediation of biological effects controlled by the cAMP-PKA pathway. This review will provide an updated overview of some of the sites of regulation by cAMP in adipogenesis and lipolysis and the involvement of AKAPs and highlighting, as a recent example, the AKAP Optical Atrophy 1 (OPA1) and its role in the phosphorylation of Perilipin to induce lipolysis.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.